157
Participants
Start Date
August 1, 2018
Primary Completion Date
August 1, 2021
Study Completion Date
October 1, 2021
Progesterone
Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
American University of Beirut Medical Center, Beirut
American University of Beirut Medical Center
OTHER